To Örebro University

oru.seÖrebro universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Whole blood viscosity in plasma cell dyscrasias
Örebro universitet, Institutionen för läkarutbildning.
Department of Medical Biosciences/Clinical Chemistry, Umeå University, Umeå, Sweden.
2015 (engelsk)Inngår i: Clinical Biochemistry, ISSN 0009-9120, E-ISSN 1873-2933, Vol. 48, nr 3, s. 122-124Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objectives: Plasma or serum hyperviscosity in plasma cell dyscrasias (PCD) has been described as a risk factor for circulatory disturbances. Whole blood viscosity (WBV) would theoretically be a better biomarker but has not been studied in PCD.

Design and methods: Plasma viscosity (PV) and WBV were measured in 89 subjects with PCD and in 60 healthy blood donors by free oscillation rheometry. A complete blood count was obtained using an automated hematology analyzer. Plasma proteins were quantitated by immunoturbidimetry.

Results: The reference intervals for men & women were 1.16-1.36 & 1.16-1.38. mPa for PV, and 4.9-6.3 & 4.4-6.2. mPa for WBV, respectively. Of the PCD patients, 71% had PV above the reference limit and 40% were above the WBV limit. Multivariate analysis showed that WBV was independently related to hematocrit, PV, concentration of the monoclonal protein (M-protein), plasma fibrinogen concentration and albumin concentration. This model accounted for 76% of the variance in WBV. When the same model was applied to PV, only the concentration of the M-protein was significantly related and the model accounted only for 20% of the variance in PV.

Conclusion: PV cannot be used as a surrogate marker for WBV in PCD patients. Whole blood viscosity should replace plasma viscosity in patients with PCD.

sted, utgiver, år, opplag, sider
Elsevier, 2015. Vol. 48, nr 3, s. 122-124
Emneord [en]
M-protein; MGUS; Myeloma; Plasma viscosity; Whole blood viscosity
HSV kategori
Forskningsprogram
Medicin
Identifikatorer
URN: urn:nbn:se:oru:diva-41639DOI: 10.1016/j.clinbiochem.2014.11.006ISI: 000348703300006PubMedID: 25526882Scopus ID: 2-s2.0-84921765352OAI: oai:DiVA.org:oru-41639DiVA, id: diva2:780748
Merknad

Funding Agency:

Örebro County Council Research Committee

Tilgjengelig fra: 2015-01-15 Laget: 2015-01-15 Sist oppdatert: 2021-02-26bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Person

Uggla, Bertil

Søk i DiVA

Av forfatter/redaktør
Uggla, Bertil
Av organisasjonen
I samme tidsskrift
Clinical Biochemistry

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 622 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf